A four-month gatifloxacin-containing regimen for treating tuberculosis

New England Journal of Medicine

Volumn 371, Issue 17, 2014, Pages 1588-1598

  Merle, Corinne S ^a   Fielding, Katherine ^a   Sow, Omou Bah ^c   Gninafon, Martin ^d   Lo, Mame B ^e   Mthiyane, Thuli ^f   Odhiambo, Joseph ^g   Amukoye, Evans ^g   Bah, Boubacar ^c   Kassa, Ferdinand ^d   N'Diaye, Alimatou ^e   Rustomjee, Roxana ^f   De Jong, Bouke C ^h   Horton, John ^b   Perronne, Christian ⁱ   Sismanidis, Charalambos ^a   Lapujade, Olivier ^j   Olliaro, Piero L ^k   Lienhardt, Christian ^j  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Tropical Projects   (United Kingdom)

^c Hopital Ignace Deen   (Guinea)

^d Centre National Hospitalier de Pneumo Phtisiologie   (Benin)

^e Programme National de Lutte Contre le SIDA   (Senegal)

^f SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^h INSTITUTE OF TROPICAL MEDICINE   (Belgium)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; DYSGLYCEMIA; FEMALE; GUINEA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INFECTION RISK; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SENEGAL; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT RESPONSE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; INTENTION TO TREAT ANALYSIS; ISOLATION AND PURIFICATION; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PHASE 3 CLINICAL TRIAL;

ADULT; ANTITUBERCULAR AGENTS; BLOOD GLUCOSE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; HUMANS; INTENTION TO TREAT ANALYSIS; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84908147456     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1315817     Document Type: Article

References (24)

1. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100-9.
2. Global tuberculosis report 2013. Geneva: World Health Organization (http://www.who.int/tb/publications/global-report/en).
3. Gospodarevskaya E, Tulloch O, Bunga C, et al. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. Int J Tuberc Lung Dis 2014;18:810-7.
4. A randomised clinical trial to trial the efficacy of intermittent regimens containing ofloxacin in the treatment of smear positive pulmonary tuberculosis: annual report 2001-2002. Tamil Nadu, India: Tuberculosis Research Center.
5. Sulochana S, Rahman F, Paramasivan CN. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005;17:169-73.
6. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-38.
7. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8.
8. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet 2009;373:1183-9.
9. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80.
10. Merle CS, Sismanidis C, Sow OB, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 2012;13:61.
11. Treatment of tuberculosis: guidelines for national programmes. 3rd ed., rev. Geneva: World Health Organization, June 2004.
12. Bazett HC. An analysis of the timerelations of electrocardiograms. Heart 1920;7:353-70.
13. Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Med Scand 1920;53:469-86.
14. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313: 36-9.
15. Erratum, BMJ 1996;313:550
16. BMI classification. Geneva: World Health Organization (http://apps.who.int/bmi/index.jsp?introPage=intro-3.html).
17. Guidance for industry - pulmonary tuberculosis: developing drugs for treatment. Rockville, MD: Food and Drug Administration, 2013 (http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM373580.pdf).
18. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:Suppl 2:S231-S279.
19. Smythe W, Merle CS, Rustomjee R, et al. Evaluation of initial and steadystate gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using Monte Carlo simulations. Antimicrob Agents Chemother 2013;57:4164-71.
20. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61.
21. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303-9.
22. Onyenwenyi AJ, Winterstein AG, Hatton RC. An evaluation of the effects of gatifloxacin on glucose homeostasis. Pharm World Sci 2008;30:544-9.
23. Jindani A, Hatherill M, Charalambous S, et al. A multicentre randomized clinical trial to evaluate high-dose rifapentine with a quinolone for treatment of pulmonary TB: the RIFAQUIN Trial. Presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. abstract.
24. Phillips PP, Nunn AJ, Paton NI. Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? Int J Tuberc Lung Dis 2013;17:807-9.